Viking Therapeutics (VKTX) leads the race to win FDA Rx-to-OTC switch for an oral weight loss drug belonging to GLP-1 class ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Terns Pharma is in the process of developing TERN-601 for the treatment of patients with obesity. See why I rate TERN stock ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

The results of Novo Nordisk’s phase 1 trials shows the oral weight loss pill could be more effective than semaglutide.

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a ...